|本期目录/Table of Contents|

[1]夏伟康,金 竹,周昌林,等.光敏剂在光动力治疗中的应用研究进展[J].武汉工程大学学报,2021,43(02):131-138.[doi:10.19843/j.cnki.CN42-1779/TQ.202010022]
 XIA Weikang,JIN Zhu,ZHOU Changlin,et al.Research Progress in Application of Photosensitizers in Photodynamic Therapy[J].Journal of Wuhan Institute of Technology,2021,43(02):131-138.[doi:10.19843/j.cnki.CN42-1779/TQ.202010022]
点击复制

光敏剂在光动力治疗中的应用研究进展(/HTML)
分享到:

《武汉工程大学学报》[ISSN:1674-2869/CN:42-1779/TQ]

卷:
43
期数:
2021年02期
页码:
131-138
栏目:
化学与化学工程
出版日期:
2021-04-30

文章信息/Info

Title:
Research Progress in Application of Photosensitizers in Photodynamic Therapy
文章编号:
1674 - 2869(2021)02 - 0131 - 08
作者:
夏伟康 金 竹周昌林汪 磊*
三峡大学材料与化工学院,湖北省无机非金属晶态与能源转换材料重点实验室,湖北 宜昌 443000
Author(s):
XIA Weikang JIN Zhu ZHOU Changlin WANG Lei *
Key Laboratory of Inorganic Nonmetallic Crystalline and Energy Conversion Materials, School of Materials and Chemical Engineering, Three Gorges University, Yichang 443000, China
关键词:
光动力治疗光敏剂癌症非侵入性低毒性
Keywords:
photodynamic therapy photosensitizer cancer non-invasive low cytotoxicity
分类号:
Q599
DOI:
10.19843/j.cnki.CN42-1779/TQ.202010022
文献标志码:
A
摘要:
光动力疗法(PDT)以其超高时空分辨率、非侵入性及低毒副作用的优点,被认为是治疗癌症和各种非恶性疾病的有效疗法之一。本文主要综述了几类光敏剂发展历史、主要结构、特点及研究进展,分析了高性能光敏剂的开发动态,包括化学修饰;与具有特定细胞受体的其他配体缀合成复合光敏剂;采取纳米技术,如纳米颗粒输送,基于富勒烯的光敏剂等。基于此,指出具有临床应用前景的高性能光敏剂的基本特征、设计原则及发展趋势。
Abstract:
Photodynamic therapy (PDT) is considered as an effective treatment of cancer and various non malignant diseases because of its advantages of super-high spatial-temporal resolution, non-invasive and low toxicity. In this paper, the development history, main structures, characteristics and research progress of several kinds of photosensitizers were reviewed. The developmental trends of high-performance photosensitizers were also analyzed, including chemical modification, compounding photosensitizers with other ligands that can be specifically received with cell, adopting nanotechnology such as nanoparticle transport, fullerene based photosensitizers, etc. Based on this, the basic characteristics, design principles and developmental trends of high-performance photosensitizers with clinical application values were pointed out.

参考文献/References:

[1] MOAN J, PENG Q. An outline of the hundred-year history of PDT[J]. Anticancer Research, 2003, 23(5A):3591-3600.

[2] 陈越,郑军,谭潇. 光动力疗法在肿瘤治疗中的研究进展[J]. 实用医学杂志,2019,35(16):2517-2521.
[3] LYNDE C, VENDER R, BOURCIER M, et al. Clinical features of external genital warts.[J].Journal of Cutaneous Medicine & Surgery, 2013, 17(6):55-60.
[4] RECHTMAN E, CIULLA T A, CRISWELL M H, et al. An update on photodynamic therapy in age-related macular degeneration[J]. Expert Opinion on Pharmacotherapy, 2002, 3(7):931-938.
[5] BERNS M W, COFFEY J, WILE A, et al. Response of psoriasis to red laser light (630 nm) following systemic injection of hematoporphyrin derivative[J]. Lasers in Surgery and Medicine, 1984, 4(1):73-77.
[6] 张玲琳,吴赟,张云凤,等. 不同光源(红光VS强脉冲光)光动力治疗寻常痤疮:半脸、随机、前瞻性研究[J]. 中国激光医学杂志,2018,27(2):97.
[7] DAI T, HUANG Y Y, HAMBLIN M R. Photodynamic therapy for localized infections-State of the art[J]. Photodiagnosis and Photodynamics Therapy, 2009, 6(3/4):170-188.
[8] 郑哲,张国龙,王秀丽. 单线态氧在光动力治疗中的作用机制及检测方法[J]. 中国激光医学杂志,2019,28(4):219-223.
[9] CASTANO A P, DEMIDOVA T N, HAMBLIN M R. Mechanisms in photodynamic therapy: part two-cellular signaling, cell metabolism and modes of cell death[J]. Photodiagnosis and Photodynamic Therapy, 2005, 2(1):1-23.
[10] LAN M H, ZHAO S J, LIU W M, et al. Photosensitizers for photodynamic therapy[J]. Advanced Healthcare Materials,2019,8(13): 1900132.[11] HOPE-SEYLER F. Beitrage zur kenntniss des blutes des menscheu und der wirbelthiere das hamatin[J]. Tubinger Med Chem Untersuchungen,1871(4): 523-533.
[12] MEYER-BETZ F. Untersuchungen über die biologische (photodynamische) wirkung des H?matoporphyrins und anderer derivate des blut-und gallenfarbstoffs[J]. Deutsches Archiv fur Klinische Medizin, 1913, 112: 476-503.
[13] POLICARD A. Etude sur les aspects offerts par des tumeurs experimentales examinees a la limiere de wood[J]. Biologue Comptes Rendus,1924,91: 1423.
[14] SCHWARTZ S, ABSOLON K, VERMUND H. Some relationships of porphyrins, X-rays and tumors[J]. University of Minnesota Medical Bulletin, 1955, 27: 7-8.
[15] ALLISON R R, SIBATA C H. Oncologic photodynamic therapy photosensitizers: a clinical review[J]. Photodiagnosis and Photodynamic Therapy, 2010, 7(2): 61-75.
[16] ABRAHAMSE H, HAMBLIN M R. New photosensi-tizers for photodynamic therapy[J]. Biochemical Journal, 2016, 473(4):347-364.
[17] 许德余,殷祥生. 肿瘤光化学诊治新药癌光啉(PsD-007)的研究[J]. 中国医药工业杂志,1989,20(10):440-446.
[18] 顾瑛,李峻亨. 血啉甲醚用于光动力疗法治疗鲜红斑痣的初步临床研究[J]. 中国激光医学杂志,1996(4):17-20.
[19] 王韬,聂双发,薛军,等. 5-ALA-PDT诱导人结肠癌HT-29细胞凋亡的机制研究[J]. 中国医师杂志,2020, 22(4):486-489.
[20] LI W T, TAN G H, ZHANG H Y, et al. Folate chitosan conjugated doxorubicin and pyropheophorbide acid nanoparticles (FCDP-NPs) for enhance photodynamic therapy[J]. RSC Advance 2017, 70 (7):44426-44437.
[21] PATTERSON M S, WILSONB C. Photodynamic therapy. In: Dyh JV, editor. The modem technology of radiation oncology[J]. Madison: Medical Physics Publishing, 1999, 9(3):71-80.
[22] PANDEY S K, ZHENG X, MORGAN J, et al. Purpurinimide carbohydrate conjugates: effect of the position of the carbohydrate moiety in photosensiti-zing efficacy [J]. Molecular Pharmaceutics, 2007, 4(3):448-464.
[23] HARRIS F, PIERPOINT L. Photodynamic therapy based on 5-aminolevulinic acid and its use as an antimicrobial agent[J]. Medicinal Research Reviews, 2012, 32(6): 1292-1327.
[24] PANDEY R K, SUMLIN A B, CONSTANTINE S, et al. Alkyl ether analogs of chlorophylla derivatives: part1.synthesis, photophysical properties and photodynamic efficacy[J]. Photochem Photobiol, 1996,64(1): 194-204.
[25] CHEN L, ZHANG X, CAO Q Q, et al. Development and application of a physiologically based pharmacokinetic model for HPPH in rats and extrapolate to humans[J]. European Journal of Pharmaceutical Sciences, 2019, 129:68-78.
[26] GURINOVICH G P, ZORINA T E, MELNOV S B, et al. Photodynamic activity of chlorin e6 and chlorin e6 ethylenediamide in vitro and in vivo[J]. Journal of Photochemistry and Photobiology B: Biology, 1992, 13(1): 51-57.
[27] RYU J H, JEONG Y I, KIM H Y, et al. Enhanced photosensing and photodynamic treatment of colon cancer cells using methoxy poly(ethylene glycol)-conjugated chlorin e6[J]. Journal of Nanoscience & Nanotechnology, 2018, 18(2):1131-1136.
[28] JONAS J, DAGE S. The aromatic pathways of porphins, chlorins and bacteriochlorins[J]. Physical Chemistry Chemical Physics, 2000, 2: 2145-2151. [29] MILLER G G, BROWN K, BALLANGRUD A M, et al. Preclinical assessment of hypocrellin B and hypocrellin B derivatives as sensitizers for photodynamic therapy of cancer: progress update[J]. Photochemistry and Photobiology, 1997, 65(4):714-722.
[30] PARK J, ENGLISH D S, WANNEMUEHLER Y, et al. The role of oxygen in the antiviral activity of hypericin and hypocrellin [J]. Photochemistry and Photobiology, 1998, 68(4): 593-597.
[31] MIROSSAY L, MIROSSAY A, KOCISOVA E, et al. Hypericin-induced phototoxicity of human leukemic cell line HL-60 is potentiated by omeprazole, an inhibitor of H+ K+-ATPase and5’-(N, N-dimethyl)-amiloride, an inhibitor of Na+/H+ exchanger [J]. Physiological Research, 1998, 48(2): 135-141.
[32] 朱文婷,许桐瑛,谢蕊,等. 姜黄素在光动力与声动力治疗恶性肿瘤中的研究进展[J]. 现代肿瘤医学,2015(22):165-168.
[33] 许川山. 中药姜黄素的光谱学特性研究[J]. 激光杂志,2005(4):86-88.
[34] SCHRAUFSTTTTER E, BERNT H. Antibacterial action of curcumin and related compounds[J]. Nature, 1949, 164(4167):456-457.
[35] YADAV R, JEE B, AWASTHI S K. Curcumin suppresses the production of pro-inflammatory cytokine interleukin-18 in lipopolysaccharide stimulated murine macrophage-like cells[J]. Indian Journal of Clinical Biochemistry, 2015, 30(1):109-112.
[36] MOTAGHINEJAD M, KARIMIAN M,MOTAGHI-NEJAD O, et al. Protective effects of various dosage of Curcumin against morphine induced apoptosis and oxidative stress in rat isolated hippocampus[J]. Pharmacological Reports, 2015, 67(2):230-235.
[37] WAGHELA B N, SHARMA A,DHUMALE S, et al. Curcumin conjugated with PLGA potentiates sustainability, anti-proliferative activity and apoptosis in human colon carcinoma cells[J]. Plos One, 2015, 10(2): e0117526.
[38] 陈瑞川,马胜平,苏金华,等. 姜黄素诱导人胃腺癌MGC80-3细胞凋亡研究[J]. 厦门大学学报(自然科学版),2000,39(3):124-128.
[39] CHENG A L, HSU C H, LIN J K, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions[J]. Anticancer Research, 2000, 21(4B):2895-2900.
[40] GARAI A, PANT I, BANERJEE S, et al. Photorelease and cellular delivery of mitocurcumin from its cytotoxic cobalt(III) complex in visible light[J]. Inorganic Chemistry, 2016,55(12): 6027-6035
[41] BANERJEE S, PRASAD P, KHAN I, et al. Mitochondria targeting photocytotoxic oxidovanadium(IV) complexes of curcumin and (acridinyl)dipyridophenazine in visible light[J]. Zeitschrift Für Anorganische Und Allgemeine Chemie, 2014, 640(6):1195-1204.
[42] 丁兰兰,栾立强,施佳伟,等. 酞菁在光动力治疗中的应用[J]. 无机化学学报,2013,29(8):1591-1598.
[43] ROSENTHAL I. Phthalocyanines as photodynamic sensitizers [J]. Photochemistry and Photobiology, 1991, 53(6): 859-870.
[44] 黄金陵,黄剑东,刘尔生,等. 酞菁配合物的结构与其光动力抗癌活性[J]. 物理化学学报,2001,17(7):662-671.
[45] 谢宝刚. 酞菁—蛋白质复合物及其作为抗癌光敏剂的研究[D]. 福州:福州大学, 2003.
[46] 陈耐生,薛金萍,黄金陵. 用于光动力治疗抗癌新药“福大赛因”的药学与I期临床研究[C]// 2010年中国药学大会暨第十届中国药师周论文集. 2010.
[47] 郑薇,陈勇军,李颖倩,等. 亚甲基蓝联合光动力疗法治疗黑色素瘤的机理研究[J]. 中国药理通讯,2010,27(4): 33-34.
[48] MA X, QU Q Y, ZHAO Y L. Targeted delivery of 5-aminolevulinic acid by multifunctional hollow mesoporous silica nanoparticles for photodynamic skin cancer therapy[J]. ACS Applied Materials & Interfaces, 2015, 7(20):10671-10676.
[49] CHEN X, DRAIN C M. Photodynamic therapy using carbohydrate conjugated porphyrins[J]. Drug Design Reviews Online, 2004, 1(3):215-234.
[50] VEDACHALAM S, CHOI B H, PASUNOOTI K K, et al. Glycosylated porphyrin derivatives and their photodynamic activity in cancer cells[J]. Medchemcomm, 2011, 2(5):371.
[51] ZHU X C, LU W T, ZHANG Y Z, et al. Imidazole-modified porphyrin as a pH-responsive sensitizer for cancer photodynamic therapy[J]. Chemical Communications, 2011, 47(37):10311-10313.
[52] CHOI Y. Selective antitumor effect of novel protease-mediated photodynamic agent[J]. Cancer Research, 2006, 66(14):7225-7229.
[53] CHAN J M, VALENCIA P M, ZHANG L, et al. Polymeric nanoparticles for drug delivery[J]. Methods in molecular biology (Clifton, N.J.), 2010, 624:163-175.
[54] KUMARI A, YADAV S K, YADAV S C. Biodegradable polymeric nanoparticles based drug delivery systems[J]. Colloids and Surfaces B: Biointerfaces, 2010, 75(1):1-18.
[55] AVCI P, ERDEM S S, HAMBLIN M R. Photodynamic therapy: one step ahead with self-assembled nanoparticles[J]. Journal of Biomedical Nanotechnology, 2014, 10(9):1937-1952.
[56] KHDAIR A, GERARD B, HANDA H, et al. Surfactant polymer nanoparticles enhance the effectiveness of anticancer photodynamic therapy[J]. Molecular Pharmaceutics, 2008, 5(5):795-807.
[57] CHOI K H, NAM K, CHO G, et al. Enhanced photodynamic anticancer activities of multifunctional magnetic nanoparticles (Fe3O4) conjugated with chlorin e6 and folic acid in prostate and breast cancer cells [J]. Nanomaterials, 2018, 8(9):722.
[58] YAMAKOSHI Y, UMEZAWA N, RYU A, et al. Active oxygen species generated from photoexcited fullerene (C60) as potential medicines: O2- versus 1O2[J]. Journal of the American Chemical Society, 2003, 125(42):12803-12809.
[59] MA H L, JIANG X L. Fullerenes as unique nanopharmaceuticals for disease treatment[J]. Science China Chemistry, 2010, 53(11): 2233-2240.[60] HOU L, YUAN Y J, REN J X, et al. In vitro and in vivo comparative study of the phototherapy anticancer activity of hyaluronic acid-modified single-walled carbon nanotubes, graphene oxide, and fullerene[J]. Journal of Nanoparticle Research, 2017, 19(8):286.
[61] LI Q, HONG L, LI H G, et al. Graphene oxide-fullerene C60 (GO-C60) hybrid for photodynamic and photothermal therapy triggered by near-infrared light[J]. Biosensors and Bioelectronics, 2017, 89: 477-482.

相似文献/References:

[1]章颖,肖欣,邓鹏星,等.1萘酚的β取代金属卟啉的合成及其抗菌活性[J].武汉工程大学学报,2008,(04):8.
 ZHANG Ying,XIAO Xin,DENG Peng xing,et al.Synthesis and antibacterial activity of βsubstituted metalporphyrins of 1naphthol[J].Journal of Wuhan Institute of Technology,2008,(02):8.

备注/Memo

备注/Memo:
收稿日期:2020-10-21基金项目:宜昌市科学技术局应用基础研究项目(A19-302-04)作者简介:夏伟康,硕士研究生。E-mail: 415097411@qq.com*通讯作者:汪 磊,博士,讲师。E-mail: lei.wang@ctgu,edu.cn引文格式:夏伟康 ,金竹,周昌林,等. 光敏剂在光动力治疗中的应用研究进展[J]. 武汉工程大学学报,2021,43(2):131-138.
更新日期/Last Update: 2021-04-26